Showing results (861-870 of 876) with videos related to
Sort By:
Pageof 88
Nature|August 10, 2022
Diverse mutational landscapes in human lymphocytesHeather E Machado, Emily Mitchell, Nina F Øbro, et al.Cell Reports|December 25, 2025
Low-input proteomics identifies vWF as a negative regulator of Tet2 mutant hematopoietic stem cell expansionMaria Jassinskaja, Daniel Bode, Monika Gonka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2017
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid LeukemiaKenneth F Bradstock, Emma Link, Juliana Di Iulio, et al.Blood|July 31, 2020
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.The Journal of Biological Chemistry|March 1, 2020
The tetraspanin Tspan15 is an essential subunit of an ADAM10 scissor complexChek Ziu Koo, Neale Harrison, Peter J Noy, et al.Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyMeletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.Blood Cancer Journal|March 27, 2024
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?Ing Soo Tiong, Meaghan Wall, Ashish Bajel, et al.Blood Advances|February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemiaConstantine S Tam, Stephen Opat, Shirley D'Sa, et al.Blood|August 30, 2023
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLGSun Loo, Andrew W Roberts, Natasha S Anstee, et al.Pageof 88